"FINANCIAL ENGINEERING:" I would think the shareho
Post# of 30028
Posted On: 09/06/2014 11:03:46 AM
"FINANCIAL ENGINEERING:" I would think the shareholder meeting on Sept. 22nd would be a good time to reveal what management had in mind to "really increase shareholder value."
PHENOGUARD: I thought Gerald was a bit mysterious when asked about it on the CC. If there was a catalyst coming from Phenoguard, saving it until right before the RS and up list in order to help drive up the pps makes sense. Gerald said the reason they moved to a bigger space in SF was so that John Commissiong could have more room to work at the Janssen Labs. That could be a clue that Janssen Labs is interested in John's work.
ACQUIRING ANOTHER ASSET: Adam Simons owns a company (Cerora) that specializes in a Concussion and AD scanner that might be of interest to AMBS, to supplement LymPro. Adam Simons is a big shot in the AD industry. He is also on our Scientific Advisory Board. Making nice with him and showing the Alzheimer's industry that he and AMBS are very tight might hold sway with AD Research Companies embracing LymPro more completely!!
GDNF PHASE 2B TRIAL RESULTS: They should be coming out shortly. They have been using Renshaw Blood Brain Barrier technology. If it works for them it will work for MANF, which has been shown to be better than GDNF.
PHENOGUARD: I thought Gerald was a bit mysterious when asked about it on the CC. If there was a catalyst coming from Phenoguard, saving it until right before the RS and up list in order to help drive up the pps makes sense. Gerald said the reason they moved to a bigger space in SF was so that John Commissiong could have more room to work at the Janssen Labs. That could be a clue that Janssen Labs is interested in John's work.
ACQUIRING ANOTHER ASSET: Adam Simons owns a company (Cerora) that specializes in a Concussion and AD scanner that might be of interest to AMBS, to supplement LymPro. Adam Simons is a big shot in the AD industry. He is also on our Scientific Advisory Board. Making nice with him and showing the Alzheimer's industry that he and AMBS are very tight might hold sway with AD Research Companies embracing LymPro more completely!!
GDNF PHASE 2B TRIAL RESULTS: They should be coming out shortly. They have been using Renshaw Blood Brain Barrier technology. If it works for them it will work for MANF, which has been shown to be better than GDNF.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼